Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$5.24 USD
-0.11 (-2.06%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $5.24 0.00 (0.00%) 6:42 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
APLT 5.24 -0.11(-2.06%)
Will APLT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLT
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Other News for APLT
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
Biotech Alert: Searches spiking for these stocks today
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia
Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases